Should I Buy BHF? BHF 2026 Analysis

Should You Buy Brighthouse Financial Inc (BHF) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

63.730

1 Day change

-0.41%

52 Week Range

66.330

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now (deal-spread setup): With BHF trading around $63.69 pre-market versus the announced $70 takeout price, the stock offers a meaningful near-term upside if the Aquarian acquisition proceeds as expected.
Deal-driven profile dominates: Current pricing/low-IV options behavior looks like merger-arbitrage positioning rather than a pure technical trend trade.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: MACD histogram -0.0772 and negatively expanding → bearish momentum persists in the very near term.
RSI: RSI(6) ~29.34 → near oversold, suggesting selling pressure may be stretched and a bounce is plausible.
Moving averages: Converging MAs → consolidation/indecision, consistent with a deal-arb “pinning” effect.
Key levels (short-term): Pivot 64.10; support 63.78 / 63.57; resistance 64.43 / 64.63. At 63.69, price is sitting just above the lower support band (tactically decent entry location if you’re buying immediately).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Open interest put/call 0.67 and volume put/call 0.04 → strongly call-skewed flow (bullish/positive deal expectations).
Volatility read: 30D IV ~4.96 with IV percentile ~1.6 → extremely low implied volatility, typical of a market pricing a high probability, relatively “known-outcome” event (e.g., pending acquisition).
Activity: Today’s volume vs 30D average ~29x → unusually active options tape, consistent with event-driven participation.

Technical Summary

Sell

Buy

Positive Catalysts

- Aquarian take-private deal at $70/share remains the dominant catalyst; multiple Street notes frame valuation as already anchored to the transaction.
- Analyst base cases generally assume deal closes (e.g., Barclays commentary).
- Pattern-based forward bias (from similar candlestick setups): modeled probabilities imply mild upside over 1D/1W and stronger over 1M (up to ~6.76% over the next month).

Neutral/Negative Catalysts

- Deal risk/uncertainty: Any perceived delay/financing/regulatory friction would pressure the deal spread.
- Technical backdrop still weak: MACD negative and expanding → downside momentum can persist short-term even near support.
- Upcoming earnings: Next earnings QDEC 2025 on 2026-02-23 (after hours) can introduce headline moves, even in a deal context.
- Sector headwinds cited by analysts: spread compression and higher technology spend expectations for life insurers.

Financial Performance

Latest quarter: 2025/Q3
Revenue: $1.816B, -10.01% YoY (top-line contraction).
Net income: $453M, +202% YoY (sharp profitability improvement).
EPS: 7.88, +220.33% YoY (very strong earnings growth vs prior year quarter).
Overall: mixed quality (revenue down), but profitability/EPS trend was strongly positive in the latest reported quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Post-deal, the Street largely shifted to neutral/market-perform style ratings as upside becomes tied to the $70 takeout.
Key changes:
- 2026-01-08 Barclays: downgraded to Equal Weight from Overweight, PT $65 (view: Aquarian deal already reflected; base case assumes deal goes through).
- 2025-11-12 Raymond James: double downgrade to Market Perform from Strong Buy (reason: deal announced; limited incremental upside vs other opportunities).
- 2025-11-06 Morgan Stanley: upgraded to Equal Weight, PT $70 (deal-driven re-rating).
- 2025-11-07 Keefe Bruyette: Market Perform, PT raised to $70.
Wall Street pros: Takeout provides a clearer value anchor; several PTs converge near $70.
Wall Street cons: After the deal announcement, many see limited standalone upside beyond the deal spread, prompting neutral ratings.

6 Analyst Rating

Wall Street analysts forecast BHF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHF is 67.6 USD with a low forecast of 63 USD and a high forecast of 70 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

5 Hold

1 Sell

Hold

Current: 63.990

Low

Averages

67.6

High

Current: 63.990

Low

Averages

67.6

High

Barclays

Alex Scott

Overweight -> Equal Weight

downgrade

$65

AI Analysis

2026-01-08

Reason

Barclays

Alex Scott

Price Target

$65

AI Analysis

2026-01-08

downgrade

Overweight -> Equal Weight

Reason

Barclays analyst Alex Scott downgraded Brighthouse Financial to Equal Weight from Overweight with a $65 price target.

Barclays

Alex Scott

Overweight -> Equal Weight

downgrade

$65

2026-01-08

Reason

Barclays

Alex Scott

Price Target

$65

2026-01-08

downgrade

Overweight -> Equal Weight

Reason

Barclays analyst Alex Scott downgraded Brighthouse Financial to Equal Weight from Overweight with an unchanged price target of $65. The firm is "cautiously optimistic" on life insurers heading into 2026, saying capital strength, cash flow, and consolidation offset headwinds like spread compression and technology spend. On Brighthouse, the analyst believes the Street has appropriately factored the Aquarian deal into the stock's valuation. Barclay's base case assumes the transaction will go through successfully and Brighthouse will be taken private.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BHF

Unlock Now

BHF Should I Buy

BHF Should I Buy

Should You Buy Brighthouse Financial Inc (BHF) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch